GSK to ship UK brands, mulls antibiotics unit sale
July 20, 2017
Pharmaceuticals | Brentford, UK
GSK has announced its intention to sell its Horlicks and MaxiNutrition brands in the UK, and has put its cephalosporins antibiotics business under strategic review. The malt-based drink and supplement brands generate annual revenues of around £30 million, while the sale will not include Horlicks' operations in India and South East Asia. The cephalosporins arm review comes as GSK has announced plans to invest more than £140 million to expand its HIV and respiratory medicine capabilities.